Načítá se...
Clinical Pharmacokinetic Characteristics of Cebranopadol, a Novel First-in-Class Analgesic
BACKGROUND AND OBJECTIVES: Cebranopadol is a novel first-in-class analgesic acting as a nociceptin/orphanin FQ peptide and opioid peptide receptor agonist with central analgesic activity. It is currently in clinical development for the treatment of chronic pain conditions. This trial focuses on the...
Uloženo v:
| Vydáno v: | Clin Pharmacokinet |
|---|---|
| Hlavní autoři: | , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Springer International Publishing
2017
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5766727/ https://ncbi.nlm.nih.gov/pubmed/28623508 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40262-017-0545-1 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|